Prognostic role of the systemic immune-inflammation index and pan-immune-inflammation value in acute methanol poisoning

系统性免疫炎症指数和泛免疫炎症值在急性甲醇中毒中的预后作用

阅读:3

Abstract

BACKGROUND/AIM: Acute methanol poisoning (MP) poses a significant public health challenge, with inflammation increasingly recognized as a key factor in its pathophysiology. Identifying accessible and reliable prognostic biomarkers could help enhance clinical outcomes. This study aimed to assess the prognostic value of the systemic immune-inflammation index (SII) and the pan-immune-inflammation value (PIV), measured upon emergency department admission, in predicting in-hospital mortality in patients with acute MP. MATERIAL AND METHODS: This retrospective study included patients diagnosed with acute MP at two tertiary care centers in Ankara, Türkiye: University of Health Sciences Dışkapı Yıldırım Beyazıt Education and Research Hospital (1 January 2015 to 1 October 2022) and Etlik City Hospital (1 October 2022 to 11 March 2025). Demographic, clinical, and laboratory data, along with treatment details and outcomes (discharge or inhospital death), were systematically recorded. RESULTS: A total of 76 patients were included, of whom 92.1% were male, with a mean age of 49.0 ± 12.4 years. During hospitalization, 48.6% (n = 37) died. Both SII and PIV values at admission were significantly higher in nonsurvivors (p < 0.001 for SII; p = 0.031 for PIV). In multivariate Cox regression analysis, higher SII (HR: 2.44; 95% CI: 1.05-5.67; p = 0.034) and PIV (HR: 2.08; 95% CI: 1.05-4.13; p = 0.030) were independently associated with increased risk of mortality. Receiver operating characteristic (ROC) analysis showed an AUC of 0.750 (95% CI: 0.649-0.865) for SII, with an optimal cutoff of 665.6 (sensitivity: 50%; specificity: 46%), and an AUC of 0.640 (95% CI: 0.519-0.769) for PIV, with an optimal cutoff of 512.5 (sensitivity: 53%; specificity: 47%). CONCLUSION: SII and PIV measured at hospital admission may have potential prognostic value in predicting inhospital mortality in patients with acute MP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。